Patient profiles and clinical utility of mepolizumab in severe eosinophilic asthma
Pranabashis Haldar Respiratory Biomedical Research Unit, Glenfield Hospital, University of Leicester, Leicester, UK Abstract: Mepolizumab (Nucala®) is an effective and specific anti-eosinophil molecular therapy that has recently been approved as add-on therapy for the management of severe eo...
| Päätekijä: | |
|---|---|
| Aineistotyyppi: | Artikkeli |
| Kieli: | English |
| Julkaistu: |
Dove Medical Press
2017-06-01
|
| Sarja: | Biologics: Targets & Therapy |
| Aiheet: | |
| Linkit: | https://www.dovepress.com/patient-profiles-and-clinical-utility-of-mepolizumab-in-severe-eosinop-peer-reviewed-article-BTT |